Gertjan Bartlema, Co-founder Populus Bio and CEO of Immodulon Therapeutics. on Innovation in Biotechs

Gertjan Bartlema, Co-founder Populus Bio and CEO of Immodulon Therapeutics. on Innovation in Biotechs

In this episode, I spoke with Gertjan Bartlema, the co-founder Populus Bio and CEO of Immodulon Therapeutics. Over 20 years in big pharma at Celgene/Amgen and then moved into the fast pace world of biotech. From here, he has been challenging the status quo and asking the question “Is our current drug development approaches sustainable?”. Gertjan highlights the need for better clinical trial designs and the importance of making objective decisions based on data. He also offers valuable insights for aspiring executives on leadership and team dynamics.

Here's what you're in:

  • How many drugs fail end-points due to Bad Leadership?
  • Why does Gertjan believe sequential and traditional drug Development can kill innovation within Drug Development?.
  • What advice does Gertjan give to those wanting to become a CEO?

Timestamps:

02:53 The Abraxane Course Correction

06:03 Gertjan’s Journey into Life Sciences

10:40 Leaving Celgene and New Ventures

15:50 Bayesian Statistics in Clinical Studies

19:27 Mistakes Companies Are Still Making Today

25:38 The Ambitious People

35:46 Advice for Aspiring Executives


About Gertjan

Gertjan Bartlemais co-founder of Populus Bio and current CEO of Immodulon Therapeutics which is running cancer trials focusing on a broad spectrum immunomodulator. He is a global biotech executive with extensive experience in EU and US operational roles and he is a member of founding Celgene EMEA management establishing EU footprint and launching Revlimid. Prior to joining Immodulon, he was the Chief Business Officer of Vico Therapeutics, and spent 12 years with Celgene, where he led the trial of Revlimid. Gertjan holds MSc in Economics from Maastricht University.


Connect with Gertjan

LinkedIn: https://www.linkedin.com/in/gertjan-bartlema/

Populus Bio: https://populusbio.com/

Immodulon Therapeutics: https://www.immodulon.com/


About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with me:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/



Opinions and comments expressed by the guest do not represent the company and are fully their own.


Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Sep 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Aug 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Aug 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Jun 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Mai 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Mai 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Mai 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mar 42min

Populært innen Business og økonomi

stopp-verden
dine-penger-pengeradet
rss-penger-polser-og-politikk
e24-podden
rss-borsmorgen-okonominyhetene
rss-pa-konto
rss-skravla-gar
pengepodden-2
utbytte
finansredaksjonen
tid-er-penger-en-podcast-med-peter-warren
stormkast-med-valebrokk-stordalen
rss-orjasater
lederpodden
livet-pa-veien-med-jan-erik-larssen
pengesnakk
morgenkaffen-med-finansavisen
lydartikler-fra-aftenposten
liberal-halvtime
rss-markedspuls-2